News
Public · Published
CMS(867.HK/8A8.SG): Ruxolitinib Phosphate Cream Approved in Singapore, Filling Gap in Vitiligo Treatment
CMS said its subsidiary Rxilient Medical received Singapore Health Sciences Authority approval on 3 November 2026 for ruxolitinib phosphate cream, branded Lumirix®, to treat non-segmental vitiligo with facial involvement in adults and adolescents aged 12 and older. The company describes it as Singapore's first topical prescription drug directly targeting vitiligo's disease mechanism.
Published:
Updated:
What happened
CMS said its subsidiary Rxilient Medical received Singapore Health Sciences Authority approval on 3 November 2026 for ruxolitinib phosphate cream, branded Lumirix®, to treat non-segmental vitiligo with facial involvement in adults and adolescents aged 12 and older. The company describes it as Singapore’s first topical prescription drug directly targeting vitiligo’s disease mechanism.
Confirmed
Global impact / market context
Approval allows CMS’s subsidiary to market Lumirix® for the specified patients in Singapore, adding another location to its existing sales in Hong Kong, Macau and Taiwan. If prescriptions and sales follow, this could add revenue and help recover development and launch costs, though the article gives no sales forecast.
Analyst inference
The announcement fits CMS’s stated strategy, launched in 2022, to use Singapore as a hub for emerging markets and connect research, production and sales. The article reports approval and existing regional sales, but provides no expected revenue, launch timing in Singapore or commercial targets.
Confirmed
What to watch
- Watch for details on when Lumirix® sales begin in Singapore and whether CMS reports prescription uptake or revenue from the newly approved treatment. Analyst inference
- Check whether CMS discloses launch spending or other costs for Singapore; those costs would affect how much sales contribute to cash available. Analyst inference
- The approval covers non-segmental vitiligo with facial involvement in adults and adolescents aged 12 and older; other uses are not stated as approved. Confirmed